Evidence mapPaperPMID 41716272Full record

ArticleFrontiers in microbiology2026

Wuji Pill and

Mengting Li, Shuiming Xiao, Yanli Wang, Tao Li, Qin Hu, Lijinchuan Dong, Yuxuan Guo, Zhe Shi, Qing Yang, Weiyan Cai and 10 more

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Mengting Li *Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Shuiming Xiao *Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Yanli Wang *Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Tao LiExperimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.
Qin HuCollege of Chemistry and Life Science, Beijing University of Technology, Beijing, China.
Lijinchuan DongInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Yuxuan GuoInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Zhe ShiDivision of Stem Cell Regulation and Application, Key Laboratory for Quality Evaluation of Bulk Herbs of Hunan Province, Hunan University of Chinese Medicine, Changsha, China.
Qing YangInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Weiyan CaiInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Qi LiInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Bo PengInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Pengyue LiInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Xiaogang WengInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Yajie WangInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Yujie LiInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Yu DongGuang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Xiaoxin ZhuInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Zipeng GongState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang, China.
Ying ChenInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Irritable bowel syndrome (IBS) is a typical disorder of gut-brain interaction (DGBI). The microbiota-gut-brain (MGB) axis is pivotal in preventing and treating IBS. Wuji Pill is a traditional Chinese medicine commonly used to treat IBS. This study aimed to investigate the mechanism by which Wuji Pill improves IBS via the MGB axis. Methods: The visceral sensitivity and colonic motor function were evaluated using the abdominal wall withdrawal reflex test and the colonic motility curve. Depression-like behavior were evaluated using sucrose preference test, open field test, novelty-suppressed feeding test, and forced swimming tests. The intestinal mucus secretion and the activation status of microglia was detected using AB-PAS staining and immunofluorescence staining, respectively. The species composition and abundance of gut microbiota were detected through 16S rRNA sequencing and RT-qPCR. Targeted metabonomics and RT-qPCR were used for metabolites and metabolic enzymes analysis. Results: In this study, Wuji Pill improved the symptoms of IBS rats and increased the relative abundance of Discussion: This study highlights the Wuji Pill may alleviate IBS symptoms by modulating

Indexed as

Akkermansia muciniphilairritable bowel syndromemicrobiota-gut-brain axistryptophan metabolismWuji Pill

Identifiers

PMID41716272
PMCPMC12913531

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.